ERBB2 and breast carcinoma: The relationship between T-bet and response to chemotherapy has not been investigated in many cancer types, and only one study showed that T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab–taxane in HER2-overexpressing breast cancer predicted better outcome [40].